Free Trial
NASDAQ:ATXS

Astria Therapeutics Q1 2025 Earnings Report

Astria Therapeutics logo
$4.99 +0.03 (+0.50%)
As of 10:39 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Astria Therapeutics EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.48
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

Astria Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Astria Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Astria Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Friday, August 8, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Astria Therapeutics Earnings Headlines

FPV Drone Innovator Secures Major Defense Contract
In May, Ukraine launched Operation Spider Web - a 117-drone FPV swarm that devastated Russian fuel depots and radar systems. The message was clear: swarm drones are the future of warfare. Now, one U.S. drone maker is capitalizing. The Nasdaq-listed company just announced the sale of its modular FPV drone systems to a major U.S. military prime contractor.
See More Astria Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Astria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astria Therapeutics and other key companies, straight to your email.

About Astria Therapeutics

Astria Therapeutics (NASDAQ:ATXS), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

View Astria Therapeutics Profile

More Earnings Resources from MarketBeat